Galmed Pharmaceuticals (GLMD) is a clinical-stage biopharmaceutical company focused on the development and commercialization of Aramchol, a novel, once-daily, oral therapy for treating liver diseases utilizing its proprietary first-in-class family of synthetic fatty-acid/bile-acid conjugates (FABACs). Aramchol is initially being developed for treating Non-Alcoholic Steato-hepatitis (NASH), a chronic disease affecting a large population, for treating patients who also suffer from obesity and insulin resistance. Galmed Pharmaceuticals, in its current legal structure, was incorporated in Israel on July 31, 2013 as a privately held company. However, Galmed’s business has been operating since 2000 under a different group of companies established in the same year. Galmed was co-founded by Professor Tuvia Gilat and Allen Baharaff, based on Professor Gilat’s extensive research in FABACs and NASH.
